Literature DB >> 26044703

Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

James H Tabibian1,2, Steven P O'Hara1,2, Christy E Trussoni1,2, Pamela S Tietz1,2, Patrick L Splinter1,2, Taofic Mounajjed3, Lee R Hagey4, Nicholas F LaRusso1,2.   

Abstract

UNLABELLED: Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, fibroinflammatory cholangiopathy. The role of the microbiota in PSC etiopathogenesis may be fundamentally important, yet remains obscure. We tested the hypothesis that germ-free (GF) mutltidrug resistance 2 knockout (mdr2(-/-) ) mice develop a distinct PSC phenotype, compared to conventionally housed (CV) mdr2(-/-) mice. Mdr2(-/-) mice (n = 12) were rederived as GF by embryo transfer, maintained in isolators, and sacrificed at 60 days in parallel with age-matched CV mdr2(-/-) mice. Serum biochemistries, gallbladder bile acids, and liver sections were examined. Histological findings were validated morphometrically, biochemically, and by immunofluorescence microscopy (IFM). Cholangiocyte senescence was assessed by p16(INK4a) in situ hybridization in liver tissue and by senescence-associated β-galactosidase staining in a culture-based model of insult-induced senescence. Serum biochemistries, including alkaline phosphatase, aspartate aminotransferase, and bilirubin, were significantly higher in GF mdr2(-/-) (P < 0.01). Primary bile acids were similar, whereas secondary bile acids were absent, in GF mdr2(-/-) mice. Fibrosis, ductular reaction, and ductopenia were significantly more severe histopathologically in GF mdr2(-/-) mice (P < 0.01) and were confirmed by hepatic morphometry, hydroxyproline assay, and IFM. Cholangiocyte senescence was significantly increased in GF mdr2(-/-) mice and abrogated in vitro by ursodeoxycholic acid (UDCA) treatment.
CONCLUSIONS: GF mdr2(-/-) mice exhibit exacerbated biochemical and histological features of PSC and increased cholangiocyte senescence, a characteristic and potential mediator of progressive biliary disease. UDCA, a commensal microbial metabolite, abrogates senescence in vitro. These findings demonstrate the importance of the commensal microbiota and its metabolites in protecting against biliary injury and suggest avenues for future studies of biomarkers and therapeutic interventions in PSC.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 26044703      PMCID: PMC4670294          DOI: 10.1002/hep.27927

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

1.  Influence of the normal flora on mucosal morphology and cellular renewal in the ileum. A comparison of germ-free and conventional mice.

Authors:  G D ABRAMS; H BAUER; H SPRINZ
Journal:  Lab Invest       Date:  1963-03       Impact factor: 5.662

Review 2.  Primary sclerosing cholangitis: epidemiology, natural history, and prognosis.

Authors:  Cynthia Levy; Keith D Lindor
Journal:  Semin Liver Dis       Date:  2006-02       Impact factor: 6.115

3.  Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB.

Authors:  Xian-Ming Chen; Steven P O'Hara; Jeremy B Nelson; Patrick L Splinter; Aaron J Small; Pamela S Tietz; Andrew H Limper; Nicholas F LaRusso
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

4.  Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.

Authors:  Magdalena Mazagova; Lirui Wang; Andrew T Anfora; Max Wissmueller; Scott A Lesley; Yukiko Miyamoto; Lars Eckmann; Suraj Dhungana; Wimal Pathmasiri; Susan Sumner; Caroline Westwater; David A Brenner; Bernd Schnabl
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

5.  Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.

Authors:  Tae-Won Kang; Tetyana Yevsa; Norman Woller; Lisa Hoenicke; Torsten Wuestefeld; Daniel Dauch; Anja Hohmeyer; Marcus Gereke; Ramona Rudalska; Anna Potapova; Marcus Iken; Mihael Vucur; Siegfried Weiss; Mathias Heikenwalder; Sadaf Khan; Jesus Gil; Dunja Bruder; Michael Manns; Peter Schirmacher; Frank Tacke; Michael Ott; Tom Luedde; Thomas Longerich; Stefan Kubicka; Lars Zender
Journal:  Nature       Date:  2011-11-09       Impact factor: 49.962

6.  Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis.

Authors:  Tobias Mueller; Claudia Beutler; Almudena Hurtado Picó; Oren Shibolet; Daniel S Pratt; Andreas Pascher; Peter Neuhaus; Bertram Wiedenmann; Thomas Berg; Daniel K Podolsky
Journal:  Liver Int       Date:  2011-09-15       Impact factor: 5.828

7.  Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries.

Authors:  B Brandsaeter; S Friman; U Broomé; H Isoniemi; M Olausson; L Bäckman; B Hansen; E Schrumpf; A Oksanen; B G Ericzon; K Höckerstedt; H Mäkisalo; P Kirkegaard; K Bjøro
Journal:  Scand J Gastroenterol       Date:  2003-11       Impact factor: 2.423

8.  Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.

Authors:  Peter Fickert; Gernot Zollner; Andrea Fuchsbichler; Conny Stumptner; Andreas H Weiglein; Frank Lammert; Hanns-Ulrich Marschall; Oleksiy Tsybrovskyy; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

9.  Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity.

Authors:  Sya N Ukena; Anurag Singh; Ulrike Dringenberg; Regina Engelhardt; Ursula Seidler; Wiebke Hansen; André Bleich; Dunja Bruder; Anke Franzke; Gerhard Rogler; Sebastian Suerbaum; Jan Buer; Florian Gunzer; Astrid M Westendorf
Journal:  PLoS One       Date:  2007-12-12       Impact factor: 3.240

Review 10.  Role of the microbiota and antibiotics in primary sclerosing cholangitis.

Authors:  James H Tabibian; Jayant A Talwalkar; Keith D Lindor
Journal:  Biomed Res Int       Date:  2013-10-22       Impact factor: 3.411

View more
  67 in total

Review 1.  Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes.

Authors:  Michael Kriss; Elizabeth C Verna; Hugo R Rosen; Catherine A Lozupone
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

2.  The "gut microbiota" hypothesis in primary sclerosing cholangitis.

Authors:  Valerio Pontecorvi; Marco Carbone; Pietro Invernizzi
Journal:  Ann Transl Med       Date:  2016-12

3.  Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b.

Authors:  Konstantina Kyritsi; Fanyin Meng; Tianhao Zhou; Nan Wu; Julie Venter; Heather Francis; Lindsey Kennedy; Paolo Onori; Antonio Franchitto; Francesca Bernuzzi; Pietro Invernizzi; Kelly McDaniel; Romina Mancinelli; Domenico Alvaro; Eugenio Gaudio; Gianfranco Alpini; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-05-12       Impact factor: 4.307

Review 4.  Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.

Authors:  Phillipp Hartmann; Huikuan Chu; Yi Duan; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-15       Impact factor: 4.052

5.  Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West?

Authors:  Nobuhiro Nakamoto; Bernd Schnabl
Journal:  Inflamm Intest Dis       Date:  2016-01-20

Review 6.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

Review 7.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 8.  Role of the Intestinal Microbiome in Cholestatic Liver Disease.

Authors:  Nicholas F LaRusso; James H Tabibian; Steven P O'Hara
Journal:  Dig Dis       Date:  2017-03-01       Impact factor: 2.404

9.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4-/- Mouse.

Authors:  Anuradha Krishnan; Tomohiro Katsumi; Maria E Guicciardi; Adiba I Azad; Nazli B Ozturk; Christy E Trussoni; Gregory J Gores
Journal:  Am J Pathol       Date:  2020-03-30       Impact factor: 4.307

10.  Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.

Authors:  Dana Tedesco; Manoj Thapa; Chui Yoke Chin; Yong Ge; Minghao Gong; Jing Li; Sanjeev Gumber; Patrick Speck; Elizabeth J Elrod; Eileen M Burd; William H Kitchens; Joseph F Magliocca; Andrew B Adams; David S Weiss; Mansour Mohamadzadeh; Arash Grakoui
Journal:  Gastroenterology       Date:  2018-02-15       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.